To determine the effect of ranolazine , an anti-ischaemic agent with anti-arrhythmic properties , on the overall burden of atrial fibrillation ( AF ) in acute coronary syndromes ( ACS ) and determine whether ranolazine reduces the long-term incidence of clinical AF after ACS .